Discontinuation of benralizumab in Canadian patients with severe eosinophilic asthma

Stephen G. Noorduyn; Karissa Johnston; Kathy Osenenko; Niroshan Sriskandarajah; Alain Gendron; Lawrence Mbuagbaw

doi:10.1183/23120541.00465-2021

Discontinuation of benralizumab in Canadian patients with severe eosinophilic asthma

Stephen G. Noorduyn, Karissa Johnston, Kathy Osenenko, Niroshan Sriskandarajah, Alain Gendron, Lawrence Mbuagbaw

ERJ Open Research 2021 7: 00465-2021; DOI: 10.1183/23120541.00465-2021

Stephen G. Noorduyn

1AstraZeneca Canada Ltd, Mississauga, ON, Canada

2Dept of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site
ORCID record for Stephen G. Noorduyn
For correspondence: stephen.noorduyn@astrazeneca.com

Karissa Johnston

3Broadstreet HEOR, Vancouver, BC, Canada

4Memorial University, St John's, NL, Canada

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Kathy Osenenko

3Broadstreet HEOR, Vancouver, BC, Canada

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Niroshan Sriskandarajah

1AstraZeneca Canada Ltd, Mississauga, ON, Canada

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Alain Gendron

5Dept of Medicine, University of Montreal, Montreal, QC, Canada

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site
ORCID record for Alain Gendron

Lawrence Mbuagbaw

2Dept of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site
ORCID record for Lawrence Mbuagbaw

Article
Figures & Data
Info & Metrics
PDF

Figures

Download figure
Open in new tab
Download powerpoint
FIGURE 1
Time to treatment discontinuation for patients initiating treatment with benralizumab in Canada a) overall and b) stratified by prior biologic exposure.

PreviousNext

Vol 7 Issue 4 Table of Contents

Table of Contents
Index by author

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Your Email *

Your Name *

Send To *

Enter multiple addresses on separate lines or separate them with commas.

You are going to email the following Discontinuation of benralizumab in Canadian patients with severe eosinophilic asthma

Message Subject (Your Name) has sent you a message from European Respiratory Society

Message Body (Your Name) thought you would like to see the European Respiratory Society web site.

Your Personal Message

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.